El interés en corto de Teladoc Health da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Teladoc Health. Los datos de interés en corto se actualizan cada dos semanas.

Teladoc Health (NYSE:TDOC) Bolsa, Informe de interés en corto

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Teladoc Health Inc

TD GLBL HLTHCR LDR INDX USD UNT ETF

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.
Analysts estimate that Teladoc Health will report an earnings per share (EPS) of $-0.27. 
Investors in Teladoc Health are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 8.91% drop in the share price on the following day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.46</td>
<td>-0.21</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.49</td>
<td>-0.17</td>
<td>-0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>-24.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730224943_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Teladoc Health were trading at $9.18 as of October 28. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 15 analyst ratings. With an average one-year price target of $10.47, there's a potential 14.05% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Certara, Schrodinger and Phreesia, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Certara is maintaining an Neutral status according to analysts, with an average 1-year price target of $16.0, indicating a potential 74.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schrodinger, with an average 1-year price target of $27.5, suggesting a potential 199.56% upside.</li>
<li>For Phreesia, analysts project an Buy trajectory, with an average 1-year price target of $29.4, indicating a potential 220.26% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Certara, Schrodinger and Phreesia, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-1.53%</td>
<td>$454.38M</td>
<td>-44.19%</td>
</tr>
<tr>
<td>Certara</td>
<td>Neutral</td>
<td>3.17%</td>
<td>$53.50M</td>
<td>-1.20%</td>
</tr>
<tr>
<td>Schrodinger</td>
<td>Neutral</td>
<td>34.51%</td>
<td>$31.34M</td>
<td>-10.94%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's performance is below average compared to its peers in terms of Revenue Growth and Gross Profit, but it is relatively better in terms of Return on Equity.
<h3>Get to Know Teladoc Health Better</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Financial Insights: Teladoc Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -1.53% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -130.39%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -44.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.06, Teladoc Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

TDOC

A Preview Of Teladoc Health's Earnings

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

CDNA

IRMD

OMCL

TCMD

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $9 to $10.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $10

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.5, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 34.38% decline, the current average is now lower than the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728410417_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Teladoc Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -1.53%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -130.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -44.19%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -21.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.06, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Teladoc Health Through Analyst Insights

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and raises the price target from $8 to $9.

Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9

<a href="https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.">https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.</a>
Two Democratic lawmakers are working to preserve health providers' right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction.&nbsp;
A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration's during the Covid-19 pandemic. Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers' new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.&nbsp;&nbsp;
The flexible rules are set to expire at the end of the year, which telehealth advocates say could threaten patient access to medications, including stimulants for ADHD and common medications used to treat opioid addiction.&nbsp;

Biotech

General

'Lawmakers Push To Let Telehealth Providers Keep Prescribing Stimulants And Addiction Treatment; Flexibility Allowed During Pandemic Is Set To Expire At Year-End' - STAT News

Analysts' ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.57, a high estimate of $17.00, and a low estimate of $8.00. Observing a downward trend, the current average is 35.67% lower than the prior average price target of $16.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1726603234_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Teladoc Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teladoc Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Breaking Down Teladoc Health's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Teladoc Health faced challenges, resulting in a decline of approximately -1.53% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -130.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -44.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teladoc Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Teladoc Health: Insights From 14 Financial Analysts

WIIM

Teladoc Health shares are trading higher after Jefferies raised its price target on the stock from $8 to $10.

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $8 to $10.

Jefferies Maintains Hold on Teladoc Health, Raises Price Target to $10

U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Monday.
Shares of Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) rose sharply during Tuesday's session after the company announced preliminary third-quarter <a href="https://www.benzinga.com/quote/CMP">revenue above estimates.</a>
Compass Minerals continues to evaluate various alternatives regarding path forward for Fortress North America.
Compass Minerals International shares jumped 24.5% to $11.47 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Talkspace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) gained 20.9% to $2.31 after the company announced it partnered with Amazon Health Services to increase awareness and discoverability of its services.</li>
<li>Gannett Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) rose 14.5% to $5.28 after Citigroup upgraded the stock from Sell to Neutral.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) surged 14% to $1.5740. Gevo, on Monday, announced it secured a U.S. Patent for the Ethanol to Olefins (ETO) process, strengthening its IP leadership in bio-based renewable fuel and chemical production.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 12.7% to $7.03. Ginkgo Bioworks launched new Protein LLM and Model API built on Google Cloud Technology.</li>
<li>Designer Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) rose 11.3% to $6.61.</li>
<li>GDS Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NYSE">GDS</a>) gained 10.7% to $17.84.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) jumped 10.4% to $9.01.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) shares rose 9.5% to $4.86. BTIG analyst David Larsen initiated coverage on Definitive Healthcare with a Buy rating and announced a price target of $7.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) rose 9.2% to $20.80.</li>
<li>Dime Community Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) gained 8% to $28.10.</li>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) jumped 8.3% to $4.29 after William Blair upgraded the stock from Market Perform to Outperform.</li>
<li>Sleep Number Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) gained 7.7% to $18.91. Piper Sandler analyst Peter Keith maintained Sleep Number with a Neutral and raised the price target from $12 to $16.</li>
<li>Icahn Enterprises L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>) rose 6.7% to $13.20 after the company announced the class action lawsuit against the company, certain directors, and officers has been dismissed without prejudice by a district court judge.</li>
<li>LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) gained 6.5% to $51.97. Baird analyst David Rescott upgraded LivaNova from Neutral to Outperform and raised the price target from $55 to $66.</li>
<li>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) rose 5.6% to $18.20 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $21 to $24.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) gained 5.3% to $123.82.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

Intraday Update

Markets

Movers

ABNB

CURV

DCOM

GEVO

LIVN

SNBR

TALK

Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">PBF Energy</h3>
<ul>
<li>The Trade: PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) 10% owner Control Empresarial de Capitales S.A. de C.V. <a href="https://www.benzinga.com/quote/ONEW/analyst-ratings">acquired a total of 845,000 shares at</a> an average price of $31.28. To acquire these shares, it cost around $26.4 million.</li>
<li>What's Happening: PBF Energy will release its earnings results for the third quarter 2024 on Thursday, Oct. 31.</li>
<li>What PBF Energy Does: PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States.</li>
</ul>
<h3 class="wp-block-heading">Heartland Express</h3>
<ul>
<li>The Trade: Heartland Express, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLD#NASDAQ">HTLD</a>) CEO Michael J Gerdin acquired a total of 50,000 shares at an average price of $11.67. To acquire these shares, it cost around $583,675.</li>
<li>What's Happening: On July 23, Heartland Express posted downbeat quarterly sales.</li>
<li>What Heartland Express Does: Heartland Express Inc is engaged in providing truckload services across the United States and Canada.</li>
</ul>
<h3 class="wp-block-heading">Teladoc Health</h3>
<ul>
<li>The Trade: Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) Director Thomas McKinley <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 4,000 shares</a> at an average price of $7.69. To acquire these shares, it cost around $30,756.</li>
<li>What's Happening: On Aug. 26, JP Morgan analyst Lisa Gill maintained Teladoc Health with a Neutral and lowered the price target from $16 to $9.</li>
<li>What Teladoc Health Does: Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

HTLD

More Than $26M Bet On PBF Energy? Check Out These 3 Stocks Executives Are Buying

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 33.46 million shares sold short, which is 25.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726074916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TDOC) - Analyzing Teladoc Health's Short Interest

JP Morgan analyst Lisa Gill maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $16 to $9.

JP Morgan Maintains Neutral on Teladoc Health, Lowers Price Target to $9

Cathie Wood&#8216;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) was once the darling of the market, boasting bold bets on disruptive technologies and <a href="https://www.benzinga.com/topic/cathie-wood">promising massive returns</a>. 
Yet, over the past five years, it&#8217;s been more like a rollercoaster with no brakes—compared to the smooth ride offered by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). 
So, what went wrong? Let&#8217;s dig into why ARKK has stagnated while the QQQ soared.
<h2 class="wp-block-heading">High Hopes, Hard Falls</h2>
ARKK made a name for itself by investing in what it called &#8220;disruptive innovation.&#8221; The fund&#8217;s top holdings include Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Roblox Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), and Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>)—companies that promised to revolutionize their industries.
But here&#8217;s the catch: disruptive doesn&#8217;t always mean profitable, at least not in the short term. While these companies had their moments in the sun, their volatility and speculative nature have led to massive swings in ARKK&#8217;s performance.
Meanwhile, QQQ has played it safe and smart. Its top holdings—Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)—are giants in their fields. 
These companies have not only weathered market storms but have also thrived, especially in the recent AI-driven tech boom. QQQ&#8217;s exposure to these steady, cash-generating behemoths has allowed it to deliver consistent returns.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/08/40177308/cathie-wood-led-ark-invest-went-shopping-for-amd-tesla-amazon-coinbase-robinhood-meta-and-palant">Cathie Wood-Led Ark Invest Went Shopping For AMD, Tesla, Amazon, Coinbase, Robinhood, Meta And Palantir Shares Amid Market Crash</a>
<h2 class="wp-block-heading">The Numbers Don't Lie</h2>
The <a href="https://etfdb.com/tool/etf-comparison/ARKK-QQQ/#overview">data</a> speaks for itself. Over the past year, ARKK has managed a mere 10% return, while QQQ has posted a 32.2%. Year-to-date, ARKK is down 10.2%, while QQQ is up 19.5%. Over the past five years, ARKK has managed a mere 3.9% return, whereas the QQQ is up 164%.
ARKK&#8217;s 5-year beta of 1.84, compared to QQQ&#8217;s 1.19, further underscores its higher risk and volatility.
But the real kicker? ARKK's expense ratio is 0.75%, significantly higher than QQQ's 0.20%. Investors are paying more for a fund that&#8217;s been underperforming—a tough pill to swallow.
<h2 class="wp-block-heading">Missed Opportunities, Pricey Predictions</h2>
ARKK&#8217;s big swings in stock picks have also cost it. Tesla, its top holding, was a major win, but the fund's predictions for stocks like Roku, Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) and Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been overly ambitious, to say the least. 
The predictions include $605 for Roku by 2026 (currently less than 10% of that) and $1,500 for Zoom (now around $60).
While ARKK pursued potential high returns by betting on future growth, QQQ focused on established performers. As a result, QQQ investors have experienced steadier returns with less volatility. ARKK, on the other hand, has faced significant challenges, and unless its high-risk, high-reward strategy begins to pay off soon, achieving those predicted returns may remain uncertain for some time.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40329069/cathie-wood-seizing-low-valuation-opportunity-among-magnificent-7-ark-invest-snaps-up-2-4m-in-al">Cathie Wood Seizing Low-Valuation Opportunity Among Magnificent 7? Ark Invest Snaps Up $2.4M In Alphabet Shares</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Sector ETFs

Specialty ETFs

Tech

ETFs

AAPL

AMZN

ARKK

AVGO

COIN

MSFT

NVDA

RBLX

ROKU

TSLA

Why ARKK Stalled As QQQ Took Off: Harsh Lessons Over Past 5 Years

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.91, a high estimate of $17.00, and a low estimate of $8.00. Highlighting a 36.16% decrease, the current average has fallen from the previous average price target of $17.09. 
<img src="https://www.benzinga.com/files/images/story/2024/1724173257_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Teladoc Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Teladoc Health's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -1.53%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -130.39%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -44.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Teladoc Health's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Teladoc Health's debt-to-equity ratio stands notably higher than the industry average, reaching 1.06. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 11 Analyst Recommendations For Teladoc Health

Cantor Fitzgerald analyst Sarah James reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and maintains $10 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Teladoc Health, Maintains $10 Price Target

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 33.46 million shares sold short, which is 25.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724090422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.48%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Teladoc Health?

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). &#8220;I have tremendous, tremendous faith in what Robert Davis [CEO of Merck]<a href="https://www.benzinga.com/general/biotech/24/08/40259483/merck-stops-lung-cancer-study-for-keytruda-combo-due-to-ineffective-results-side-effects"> is doing,&#8221; he added.</a>
When asked about Teladoc Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), he said, &#8220;What's going on there, right now we've got this Cathie Wood, she sells the stock almost every day. She bought it much higher, it's really painful to watch.&#8221;
Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) reported a &#8220;very good&#8221; quarter, he said. &#8220;I remain committed to Nikesh Arora [CEO of Palo Alto Networks] and Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), which I think is doing the best of all of them.&#8221;
Enova International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) is a &#8220;little dicey,&#8221; Cramer said, &#8220;A little dicey because it's untraditional lending. I am just a traditionalist. I say go with the stock that collapsed over the last week, go with Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>).&#8221;
&#8220;This is enterprise software, and, you know, there is more money being lost in enterprise software in 2024 than in any other sector, so I can't play, I'm sorry,&#8221; Cramer said when asked about Bentley Systems, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>).
GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) reported a &#8220;decent&#8221; quarter and has been hurt by China, he said. &#8220;I bought the worst of the three, and I'm not proud of myself.&#8221;
Price Action:
<ul>
<li>Teladoc Health shares gained 0.7% to settle at $7.21 on Thursday.</li>
<li>Fortinet shares fell 1.8% to close at $68.68.</li>
<li>Merck shares gained 1.3% to close at $113.92.</li>
<li>Enova International shares rose 1.7% to close at $76.85.</li>
<li>GE Healthcare shares gained 3.8% to settle at $82.32 on Thursday.</li>
<li>Bentley Systems shares rose 5.1% to close at $49.25 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40277332/s-p-500-records-best-session-since-january-2023-investor-sentiment-improves-but-greed-index-remains">S&amp;P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>
Photo: Shutterstock

Media

ENVA

FTNT

GEHC

PANW

'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks

Piper Sandler analyst Jessica Tassan maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and lowers the price target from $25 to $10.

Piper Sandler Maintains Overweight on Teladoc Health, Lowers Price Target to $10

Deutsche Bank analyst George Hill maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $15 to $10.

Deutsche Bank Maintains Hold on Teladoc Health, Lowers Price Target to $10

An announcement from Teladoc ( ($TDOC) ) is now available. Michael Waters, Teladoc Health's COO, has resigned due to changes in the executive struc...

Teladoc COO Michael Waters Resigns, Receives Exit Package

In a report released today, Stephanie Davis from Barclays assigned a Buy rating to Teladoc (TDOC – Research Report), with a price target of $10.00....

Barclays Releases a Buy Rating on Teladoc (TDOC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), Brookdale Senior...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Brookdale Senior Living (BKD) and Vertex Pharmaceuticals (VRTX)

DEA set to extend COVID-era telehealth prescribing rules: Politico

Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition

Analyst Allen Lutz from Bank of America Securities maintained a Hold rating on Teladoc (TDOC – Research Report) and keeping the price target at $9....

Teladoc's Mixed Performance and Uncertain Future Lead to Hold Rating Recommendation

In a report released today, Charles Rhyee from TD Cowen maintained a Hold rating on Teladoc (TDOC – Research Report), with a price target of $9.00....

TD Cowen Remains a Hold on Teladoc (TDOC)

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Teladoc (TDOC – Research Report), with a price target of $10.0...

Barclays Keeps Their Buy Rating on Teladoc (TDOC)

This week, several major companies will be reporting earnings. Among them are Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), Meta Platforms (META) ...

Comments

Teladoc Health

Interés en corto

Teladoc Health (NYSE:TDOC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL